Ali-Jackson Kamil

Ali-Jackson Kamil is listed in filings as Director at Rigel Pharmaceuticals, Inc.. This profile follows SEC Form 4 activity through May 28, 2026, including sale activity. Recent filings connect the profile to Rigel Pharmaceuticals, Inc. (RIGL) and PDS Biotechnology Corporation (PDSB). The current snapshot covers public activity from Jun 25, 2024 to May 28, 2026. Reported amounts are shown as $72.9K to $39.7K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.